News & Press Releases

December 14, 2016

Imara Lauds Signing of 21st Century Cures Act

Many of the bill’s provisions align with company’s goal to bring innovative treatments to patients faster and more efficiently

Learn More
December 5, 2016

Imara Presents Results for IMR-687, a PDE9 Inhibitor, in Sickle Cell Disease at ASH

Positive preclinical results provided support to initiate clinical development program

Learn More
November 18, 2016

Imara Announces First Subject Dosed in Phase 1 Study of Lead Product Candidate, IMR-687

Clinical trial to evaluate the safety and tolerability of a potentially disease-modifying medicine for the treatment of sickle cell disease

Learn More
April 14, 2016

Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Disease

Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc.

Learn More